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INTRODUCTION 
In Washington v. Glucksberg, 1 the Supreme Court recognized that a "good physician is 
not just a mechanic of the human body whose services have no bearing on a person's 
moral choices, but one who does more than treat symptoms, one who ministers to the 
patient."2 The doctor-patient relationship is a highly personal one where doctors, by 
virtue of their relationship with a patient and knowledge of his medical condition, can 
best advise the patient.3 This relationship has traditionally been treated as a sacrosanct 
relationship with fiduciary duties.4 The duties imposed on doctors involve fully 
informing the patient about treatment options and maintaining the established standard 
of care. 5 Traditional legal principles, such as medical malpractice and informed consent, 
help ensure that doctors deliver the best possible care.6 
It is especially important to protect the doctor-patient relationship when dealing with a 
life-threatening condition such as Opioid Use Disorder ("OUD").7 Unfortunately, the 
most effective treatment for OUD, the use ofbuprenorphine, is currently also one of the 
most restricted treatments in the field of medicine. 8 The treatment of OUD is the only 
area of medicine in which a doctor's ability to prescribe a certain drug is limited by the 
number of patients that the doctor treats. 9 This restriction is especially egregious since 
buprenorphine is a potentially lifesaving medication during a nationwide epidemic. 10 
1 521 U.S. 702 (1997). 
2 Id. at 779 (Souter, J., concurring) (citing Roe v. Wade, 410 U.S. 113, 153 (1973)). 
3 Desimini v. Bristol Hosp., Inc., 927 A.2d 1004, 1007 (Conn. Super. Ct. 2007) (citing Sherwood 
v. Danbury Hospital, 896 A.2d 777 (Conn. 2006)); Vitanza v. Upjohn Co., 778 A.2d 829 (Conn. 
2001 )). 
4 Wohlgemuth v. Meyer, 293 P2d 816, 820 (Cal. Dist. Ct. App. 1956). 
5 Paden v: Rudd, 669 S.E.2d 548, 550 (Ga. CL App. 2008). 
6 For an explanation of the progression of medical malpractice standards see Peter Moffett & 
Gregory Moore, The Standard of Care: Legal History The Bad and Good News, 
12 WEST. J. EMERGENCY MED. 109, 109-112 (2011). Even with the current "minimally competent 
physician" standard, described by Moffet and Moore, malpractice still serves as a measuring stick 
for maintaining a certain quality of care. Id at 110-12; See also Michael C. Barnes & Daniel C. 
McClughen, Warm Hando.!Js: The Duty Departments 
in Reducing the Risk of Subsequent Drug Overdoses, 48 U. MEM. L. REv. 1099, 1130-42 (2018) 
(explaining potential medical malpractice liability for hospitals who release patients without a wam1 
handoff policy). 
7 See Joshua W. Elder et. al., Optimal Implementation of Prescription Drug i\1onitoring 
Programs in the Emergency Department, 19 WEST. J. EMERGENCY MED. 387, 387 (2018) (describing 
OUD as the "most significant modern-day, public health crisis"). 
8 See notes 51-5 8 and accompanying text. 
9 30 100 Patient Limit, NAT'L ALLIANCE OF ADvoc. FOR BuPRENORPHINE TREATMENT, https://www. 
naabt.org/30_patient_limit.cfm [hereinafter 30 100 Patient Limit]. 
10 See and Buprenorphine: Opioid Agonist Substitution Tapers, PROVIDERS 
CLINICAL SUPPORT SYS., (Dec. 6, 2017), https://pcssnow.org/resource/methadone-buprenorphine-
opioid-agonist-substitution-tapers (describing how blocking withdrawal symptoms and reducing 
cravings reduces the risk of relapse). 
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Another threat to the doctor-patient relationship is unfair business practices. Market 
leading businesses, which range from addiction recovery centers to behavioral healthcare 
hospitals, present outdated abstinence treatment methods as superior to medication-
assisted treatment. 11 Twelve-step abstinence-based treatment programs reject the use 
ofbuprenorphine; therefore, these businesses do not provide the necessary institutional 
support required for the growth of buprenorphine-medication assisted treatment 
("B-MAT").I2 However, outcome-based research clearly shows that medication-
assisted treatment ("MAT") with medicines like buprenorphine is dramatically superior 
to abstinence. 13 Alex Azar, Secretary of the U.S. Department of Health and Human 
Services (HHS), has stated that not offering MAT is like "trying to treat an infection 
without antibiotics."I4 
One of the most prominent threats to the doctor-OUD patient relationship is patient 
discrimination; doctors often see OUD patients as "moral failures" rather than people 
affected by a chronic condition. Is Further, Congress continues to display bias by 
imposing limits on buprenorphine prescribing, I6 and, in the past, doctors were even 
disciplined for prescribing opiates for maintenance. I 7 However, the focus of this Article 
is not to discuss whether a bias exists toward OUD patients; instead, it proposes that 
informed consent has the potential to serve as more than a 'checkbox' to avoid litigation, 
and genuinely enhance the doctor-OUD patient relationship. Regardless of the existing 
bias, OUD patients should have the right to self-determination. Is 
Given its life-and-death ramifications, OUD treatment provides a valuable case study 
of the benefits of informed consent on patient treatment.I9 According to a 2019 study, 
opioid deaths are expected to skyrocket by 2025, and researchers have identified the 
11 See e.g., notes 99-101 and accompanying text 
12 See e.g., Katrine Jo Andersen & Cecilie Maria Kallestrup, · How the 12 
Program and Its the Crisis, NEw REPUBLIC (June 
27, 2018), (describing a Louisville, Kentuckj 
native's experience feeling like a "fraud" in a 12-step program because he was also prescribed 
suboxone ). 
13 See Alex M. Azar, to National Governors Association (Feb. 24, 2018) 
(transcript available at https://W>vwhhs.gov/about/leadership/secretary/speeches/2018-speeches/ 
chances of a fatal overdose 
14 Id 
15 See Robert Heimer et aL, ,.,,,.,,vn,,,,m 1vw'°""'~""'mu·ms 
that MAT can "reduce[] future 
Use Disorders in the United 
and Public Health Responses, 69 CLINICAL INFECTIOUS DrsEASES 546, 
548 (2018) the misconception ofaddicts as moral failures). 
16 See notes 52-57 and text 
17 See Webb v. United States, 249 US. 96, 99 (1919) (holding that a physician cannot prescribe 
opiates to a person from addiction). 
18 See Jenny Lindberg et aL, Temporising 
Ernrcs 161, 161 (2019) (explaining that self-detennination, in the '1rn'.trnr-n:1t1 
context, means that it is the who should decide which treatment option to pursue). 
19 Qiushi Chen et aL, Prevention Overdose Deaths in 
the United States, JAMA NETWORK 1, 9 (2019), https://jamanetworkcom/journals/jamanetworkopen/ 
fullarticle/2723405. 
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need for a "multipronged approach" that identifies those with OUD and improves their 
access to medications for treatment.20 This Article proposes that an improved informed 
consent structure, tailored to the provider-ODD patient relationship, can play a role 
in narrowing the treatment gap by destigmatizing those with OUD, placing them in a 
decision-making position, and showing that understanding and accessing MAT does not 
have to be so difficult. 21 
While other Articles have discussed potential factors that may contribute to the limited 
utilization of MAT with buprenorphine, this Article will specifically analyze the unique 
legal factors involved. First, in Section I, this Article will review the history of drug 
regulation, and explain how legislation has adapted in response to the dramatic changes 
in opioid use that have taken place, particularly over the past two decades.22 Next, in 
Section II, this Article will present a novel perspective on how fully informing patients 
of their available treatment options will create a dynamic shift away from unfair business 
practices that restrain the doctor-OUD patient relationship.23 Next, Section III proposes 
a tailored list of best practices, specific to the OUD treatment setting, that doctors should 
implement when securing informed consent.24 Finally, this Article suggests that the 
legal profession, legislators, and government agencies can play an important role in 
making lifesaving treatment more readily available. 
I. BACKGROUND 
A. History of Drug Regulation 
The United States has a long history of drug regulation designed to prevent opioid 
abuse.25 In the early l 900's, legislation involving opioids started to become progressively 
more restrictive.26 Regulation began with ingredient disclosure (1906 Pure Food and 
Drug Act) and truthful labeling (1912 Sherley Amendmentto the Pure Food and Drug 
Act) requirements for products containing opioids.27 Next, opioid distribution itself was 
limited by the Harrison Narcotics Tax Act of 1914,28 which allowed for the distribution 
of opiates by a physician only "in the course of his professional practice."29 Because 
20 
Levy's belief that the idea that a person is 




in the United States, U.S. FooD & DRUG ADMIN., hm,0·1m""'" 
amrlm.en1"1 u·~'+11Li<mvm11oau [hereinafter Milestones]. 
26 Pure Food and Drug Act of 1906, Pub. L No. 59-384, 34 Stat 768 (1906). 
Id; Pure FoodandDrugActof 1906, Pub. L No. 62-301, 37 Stat 416, 417 (1912);Milestones, 
supra note 25. 
28 See Harrison Narcotics Tax Act, Pub. L No. 63-223, 38 Stat 785 (1914) 
for addiction treatment is "so a ,.,,.,, . ..,Pro""' 
29 Id; v. United States, 271 US. 104, 105 (1926). 
31 
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addiction was considered a moral failing and not a disease, doctors were not allowed 
to prescribe opiates for addiction treatment.30 Twelve-step abstinence programs were 
established as a result of this emphasis on addiction as a moral failing and the resulting 
limitations on medical treatment.31 Alcohol addiction was the first disorder addressed 
when Alcoholics Anonymous was formed (AA) in 1935.32 Next, in 1953, Narcotics 
Anonymous (NA) was built on the same twelve-step principles.33 
While the number of abstinence programs continued to increase, regulation of opioids 
also continued with the passage of the Controlled Substances Act (CSA),34 which was 
passed as part of the Comprehensive Drug Abuse Prevention and Control Act of 1970.35 
The CSA created five controlled drug classifications (schedules 1-V) and a "closed 
system" in which anyone authorized by the Drug Enforcement Agency (DEA) to handle 
controlled substances had to register.36 
Finally, in 1974, physicians could once again use opioids to treat OUD patients.37 
Methadone, a long-acting opioid, proved effective in controlling withdrawal symptoms, 
and in 1972 the Food and Drug Administration (FDA) approved its use for the treatment 
of opioid addiction.38 The Narcotic Addict Treatment Act of 1974 allowed federally 
licensed programs ("methadone clinics"), but not individual physicians, to dispense 
medication for "detoxification" or "maintenance" purposes.39 During this period, 
researchers were also working on developing buprenorphine.40 Buprenorphine was 
unique because it had a limited maximum or "ceiling" effect and a long half-life.41 Such 
30 Webb v. United States, 249 US. 96, 99-100 (1919). 
31 See notes 32-33 and accompanying text 
32 Over 80 Years ALCOHOLICS ANONYMOUS, https:/hvww.aa.org/pages/enUS/aa-timeline; 
see also Historical Data: The Birth and Its Growth in the US/Canada, ALCOHOLICS 
ANONYMOUS, https://www.aa.org/pages/en_US/historical-data-the-birth-of-aa-and-its-growth-in-the-
uscanada that "AA. had its beginnings in 1935 at Akron, Ohio, as the outcome of a meeting 
between Bill W, a New York stockbroker, and Dr. Bob S., an Akron surgeon."). In 1939 the program 
"published its basic textbook, Id. 
33 About NA, NARCOTICS ANONYMOUS, https://www.na.org/aboutus/?ID=PR-index. 
34 21 US.C. § 812 et seq. (1970). 
35 Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L No. 91-513, 84 Stat 
1236 (1970). 
36 See 21 US.C. § 812; Diversion Control Division, Resources, US. DEPT. OF JusnCE, https:// 
wvvw.deadiversion. usdoj .gov/21 cfr/ cfr/2108cfrt.htm (explaining the five schedules and process for 
registration). 
37 Narcotic Addict Treatment Act of 1974, Pub. L No. 93-281, 88 Stat 124 (1974). 
38 Rebecca L Haffajee et al., to Address Provider Barriers to 
jjuon:norv~1me Treatment, 54 AM. l PREVENTATIVE MED. S230, S231 (2018). 
39 § 303, 88 Stat at 124; A History of Opiate Laws in the United States, NAT'LALL. OF ADVOCATES 
FOR BuPRENORPHINE TREATMENT, http://W\v\lv.naabt.org/laws.cfm (last visited Sept 16, 2019). 
40 Nancy D. Campbell & Anne M. Lovell, The History Development as an 
Addiction 1248 ANNALS NY AcAD. ScL 124, 131-37 (2012). 
41 Id; see supra note 10 (stating that buprenorphine's "ceiling effect" makes it safer than other 
opioids). 
32 
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features made buprenorphine ideal for the treatment of withdrawal because it requires 
only a single daily dose and reduces the risks associated with methadone.42 
Buprenorphine has proven to be effective. For example, in 1995, France (where 
primary care doctors are the primary prescribers of buprenorphine and may prescribe 
it without any special license or training) first allowed doctors to prescribe the drug 
for the treatment of OUD, and within four years the number of deaths caused by 
overdose declined by seventy-nine percent.43 In the United States, the medical use of 
opioids significantly increased in the 1990's when doctors began to treat pain more 
aggressively.44 In the mid-1990's, the American Pain Society proposed the recognition 
of pain monitoring as a "fifth vital sign," and in 2000, hospital systems such as the 
Veterans Health Administration (VA) began to recognize it as such.45 Subsequently, in 
2001, the Joint Commission46 accepted such monitoring as one of its standards.47 Along 
with an increase in opioid prescriptions, there was a parallel increase in the number of 
diagnoses ofOUD.48 By this time, the abstinence model was a prominent treatment for 
the growing number ofOUD patients.49 
The United States subsequently established stricter regulations concerning the use 
of buprenorphine for OUD treatment, and relaxation of these regulations has been 
slow.50 For instance, the Drug Addiction Treatment Act of 2000 (DATA 2000) allowed 
42 Methadone does not have a ceiling effect like buprenorphine does, so as the dose of methadone 
increases so do the risks of side effects such as impairment, respiratory depression, and even death. 
See Haffajee, supra note 38, at S232; Buprenorphine, SuBSTANCE ABUSE AND MENTAL HEALTH SERVS. 
ADMIN., https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine (last 
visited Nov. 2, 2019). 
43 Marc Amiacombe et aL, French Field Experience with Buprenorphine, 13 AM. J ADDICTIONS. 
Sl7, S17, S19, S25 (2004). 
44 Andrew Rosenblum et aL, Opioids and the Treatment of Chronic Pain: Controversies, Current 
Status, and Future Directions, 16 EXPERIMENTAL AND CLINICAL PsvcHOPHARMACOLOGY 405, 406 
(2008). 
45 See Pain as the 5th Vital Sign Toolkit, DEPT. OF VETERANS AFF., https://www.va.gov/ 
PAINMANAGEMENT/docs/Pain_As_the_5th_ Vital_Sign_Toolkitpdf (stating that "the phrase 
'pain as the 5th vital sign' was initially promoted by the American Pain Society to elevate awareness 
of pain treatment among healthcare professionals."). 
46 See About the Joint Commission, JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE 0RG., 
https://www.jointcommission.org/about_us/about_the_joint_commission_main.aspx [hereinafter 
JOINT COMMISSION]. The Joint Commission is an independent, not-for-profit organization that 
accredits and certifies over 22,000 health care organizations and programs throughout the United 
States for quality and meeting specific performance standards. Id 
47 See The Joint Commissions Pain Standards: Origins and Evolution 1, 2, JOINT COMMISSION, 
https://vv,,rwjointcommission.org/assets/1/6/Pain_Std_History _Web_ Version_OS 122017 .pdf 
(explaining the Joint Commission's 2001 introduction of standards for organizations to provide 
better care to patients in pain). 
48 See Paige M. Smith, Implementing Medicaid Health Homes to Provide Medication Assisted 
Treatment to Opioid Dependent Medicaid Beneficiaries, 106 Kv. L REv. 112, 112 (2017) 
(describing overdoses and OUD as an "unanticipated consequence" increased prescribing). 
49 See Andersen, supra note 12 (describing detox wards, in which patients addicted to opioids stay 
while they experience vvithdrawal symptoms from quitting opioids "cold turkey"). 
so See generally infra notes 51-58 and accompanying text 
33 
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physicians who met certain qualifications and conditions to treat OUD patients with 
schedule III, IV, and V medications. 51 Since buprenorphine is the only Schedule III-V 
medication approved by the FDA for the treatment of OUD, DATA 2000 exclusively 
applies to its use for the treatment of OUD.52 Under DATA 2000, physicians were 
capped at a thirty patient limit, marking the first time that doctors were limited to a 
certain number of prescriptions they are allowed to prescribe.53 The 2006 Office of 
National Drug Control Policy Reauthorization Act included legislation that advocated 
for the increase of patient limits from thirty to one hundred patients after one year of 
practice.54 Ten years later, an HHS regulation allowed qualified physicians to increase 
their patient limit to 275 patients,55 and the Comprehensive Addiction Recovery Act of 
2016 ("CARA") allowed "qualified practitioners,"56 including nurse practitioners and 
physician assistants, to treat up to thirty patients during their first year and one hundred 
patients after the first year. 57 Then, in 2018, the Substance Use-Disorder Prevention That 
Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities 
Act expanded the group of"qualifying other practitioner[ s ]"who could provide B-MAT 
to include "clinical nurse specialists, certified registered nurse anesthetists, and certified 
nurse midwives" for a five year period in response to the epidemic.58 
51 Drug Addiction Treatment Act of 2000, Pub. L. No. 106-310, §3502, 114 Stat. 123-25 
(2000); Drug Scheduling, U.S. DRUG ENFORCEMENT ADMIN., https://www.dea.gov/drug-scheduling 
[hereinafter Drug Scheduling] (explaining that the Drug Enforcement Administration classifies 
Schedule HI drugs as having moderate to low potential for physical and psychological dependence, 
Schedule IV drugs as having a low potential for abuse and risk of dependence, and Schedule V 
drugs as having a lower potential for abuse than Schedule IV drugs and containing limited quantities 
of certain narcotics). 
52 Drug Scheduling, supra note 51; 30 JOO Patient Limit, supra note 9. Buprenorphine is a 
schedule UI drug, while Methadone is a schedule H drug. Naltrexone is not scheduled. Drug 
Scheduling, supra note 51. 
53 See 30 100 Patient Limit, supra note 9 (stating that "no other medications have such restrictions, 
including prescription drugs people get addicted to and die from"). 
54 Office of National Drug Control Policy Reauthorization Act, Pub. L. No. 109-469 (formerly 
H.R.6344), Title XI, § 1102 (2006). 
55 Medication Assisted Treatment for Opioid Use Disorders, 42 C.F.R. §8.610 2016. 
56 See Comprehensive Addiction and Recovery Act of 2016, Pub. L. No. 114-198, 130 Stat. 
695, 720-23 (2016). As defined in the Comprehensive Addiction and Recovery Act ("CARA"), 
a qualifying physician must be licensed under state law and satisfy one or more of the following 
requirements: hold a subspecialty board certification in addiction psychiatry from the American 
Board of Medical Specialties, hold an addiction certification from the American Society of 
Addiction Medicine, or a subspecialty board certification in addiction medicine from the American 
Osteopathic Association; complete a minimum of eight hours of training in a specific location; 
must had participated as an investigator in a clinical trial leading to approval of a schedule III, Iv, 
or V narcotic; have additional training that either the state licensing board or Secretary of Health 
and Human Services deems sufficient. Id. Further, a qualifying practitioner, which includes nurse 
practitioners and physician's assistants must hold licensure under state law to prescribe schedule HI, 
rv; and V pain medications, complete a minimum 24 hours of training as outlined by the Act, and 
work with or under the supervision of a qualifying practitioner. Id. 
s1 Id. 
58 Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients 
and Communities Act, Pub. L. No. 115-271, 132 Stat. 3894(2018); Resources: Buprenorphine 
Waiver Management, AM. Soc'y OF ADDICTION MED., https://www.asam.org/resources/practice-
34 
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B. Statistics 
Since the rates of opioid prescriptions began to increase in the 1990's, the number of 
overdoses and deaths from synthetic opioid use has also steadily increased.59 Between 
1999 and 2016, the number of deaths involving prescription opioids increased 
fivefold%nearly 64,000 Americans overdosed in the latter year.60 In 2019, opioid 
overdoses surpassed car accidents as a leading cause of preventable deaths.61 According 
to data from the Substance Abuse and Mental Health Services Administration 
(SAMHSA), approximately 2.1 million Americans over the age of twelve are believed 
to have an opioid use disorder.62 
From July 2016 to September 2017, opioid overdoses increased thirty percent m 
fifty-two areas across forty-five states, which led HHS to declare opioid addiction a 
public health emergency in 2017.63 Additionally, the Centers for Disease Control and 
Prevention (CDC) estimates that nearly every eight minutes, an American dies of a drug 
overdose.64 Further, opioid misuse has resulted in many life-threatening infections65 
resources/buprenorphine-waiver-management#bupauthority (last visited Nov. 2, 2019) [hereinafter 
ASAM]; Buprenorphine Patient Limits: History and Overview NAT'L Ass'N OF STATE ALCOHOL AND 
DRUG ABUSE DIRECTORS, https://nasadad.org/wp-content/uploads/2019/0 l/Buprenorphine-Patient-
Limits-1.pdf (last visited Nov. 2, 2019). 
59 See Christopher Ingraham, CDC Releases Grim New Opioid Overdose: 'We 're Talking About 
More Than an Exponential Increase, 'WASH. PosT, (Dec. 21, 2017), https://www.washingtonpost 
com/news/wonk/wp/2017 /12/21/ cdc-releases-grim-new-opioid-overdose-figures-were-talking-
about-more-than-an-exponential-increase/ (presenting statistics showing a 2016 surge in deaths from 
fentanyl and other synthetic opiates). 
60 Opioid Overuse: Overview, CTR. FOR DISEASE CONTROL AND PREVENTION, https://www.cdc.gov/ 
drug overdose/ data/prescribing/ overview.html [hereinafter CDC]. 
61 Tauren Dyson, Opioid Overdoses Top Jvlotor Vehicle Crashes as Cause of Preventable 
Death, UPI: HEALTH NEws, (Jan. 14, 2019), https://www.upi.com/Health_News/2019/0l/14/ 
Opioid-overdoses-top-motor-vehicle-crashes-as-cause-of-preventable-death/663154 7 4 7 4852/?st_ 
rec=4591547584097. 
62 Rebecca Ahrnsbrak et al., Key Substance Use and Mental Health Indicators in the United States: 
Results from the 2016 National Survey on Drug Use and Health, SuBSTANCE ABUSE AND MENTAL 
HEALrH SERVICES AD MIN. (Sept 2017), https://www.samhsa.gov/data/sites/default/files/NSDlJH-
FFRl-2016/NSDUH-FFRl-2016.htm [hereinafter SAMHSA]. 
63 See Opioid Overdoses Treated in Emergency Departments: ldenti.fY Opportunities for Action, 
CDC, https://www.cdc.gov/vitalsigns/opioid-overdoses/index.html (stating that this increase was 
even more drastic in some larger cities and in the Midwestern region of the country); HHS Acting 
Secretary Declares Public Health Emergency to Address National Opioid Crisis, DEP'T OF HEALTH 
& HuMAN SERV. (Oct 26, 2017), https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-
declares-public-health-emergency-address-national-opioid-crisis.html [hereinafter HHS]. 
64 Statement of Commissioner Ro hit Chopra, FTC, (July 11, 2019), https://www.ftc.gov/system/ 
files/documents/public_statements/1534673/chopra_-_reckitt_statement_ 7-11-19 .pdf. See also 
National Kickoff Call: OPIS-S2 (Opioid Prevention in States-Surge Support) via the Cooperative 
Agreement for Emergency Response, CTR. FOR DISEASE CONTROL: NAT'L CTR. FOR INJURY PREVENTION 
AND CONTROL (Sept.12, 2018), https://www.cdc.gov/cpr/readiness/OO_docs/Opioid_Crisis_CoAg_ 
National_Call_Slide_Deck_September_13_Final-a_Sept_l8.pdf. 
65 Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs: A 
Treatment Improvement Protocol (TIP 43), ASAM, 1, 163-64, https://www.asam.org/docs/ 
advocacy/samhsa_tip43 _matforopioidaddiction.pdf?sfvrsn=O (last visited Nov. 2, 2019). 
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and over one thousand opioid-related emergency room visits per day.66 Lastly, opioid 
misuse also carries an astronomical economic burden; the CDC estimates that its 
costs, including health care, lost productivity, addiction treatment, and criminal justice 
involvement, exceed $78.5 billion per year in the United States.67 
The number of patients seeking treatment also continues to increase.68 For example, 
the number of treatment facility admissions for opioid use increased fifty-eight percent 
between 2005 and 2015.69 Unfortunately, the majority of those suffering from OUD are 
not receiving effective treatment.70 According to a 2016 report by the Surgeon General, 
only ten percent of people with a drug use disorder received specialty treatment due 
to a lack of access to care.71 Even when patients receive treatment, data suggests that 
less than half of treatment facilities offer opioid addiction medications. 72 SAMHSA 
data through 2015 showed that only 41.2 percent of more than 12,000 drug addiction 
treatment facilities in the United States provided at least one kind of medication for 
the treatment of opioid addiction.73 Likewise, only 6.1 percent of treatment facilities 
offered all three medications approved by the FDA for OUD treatment (buprenorphine, 
methadone, and naltrexone ). 74 This data suggests that the abstinence model continues to 
dominate OUD treatment.75 
66 CSC Launches Campaign to Help States Fight Prescription Opioid Epidemic, CDC (Sept. 25, 
2017), https://www.cdc.gov/media/releases/2017 /p0925-rx-awareness-campaigns.html. 
67 Rita Milios, Opioid Abuse: A Crisis and a Challenge, RECOVERY.ORG: AM. ADDICTION CTR. 
RESOURCE (Oct.2, 2017), https://www.recovery.org/pro/articles/opioid-abuse-a-crisis-and-a-
challenge/; See also Curtis Florence et al., The Economic Burden of Prescription Opioid Overdose, 
Abuse, in ihe United States, 2013, 54 MED. CARE. 899, 901-06 (2016). 
68 Treatment Episode Data Set (TEDS) 2005 2015, SAMHSA, https://wwwdasis.samhsa.gov/ 
dasis2/teds_pubs/2015 _teds_rpt_natl.pdf (last visited Sept 16, 2019) [hereinafter TEDS]. 
69 Id; Dem1is McCarty et al., Treatment and Prevention Use Disorder: 
39 ANNU. REv. PuB. HEALTH 525, 531 (2018). 
70 See e.g., Executive Surgeon General :S Report on Alcohol, Drugs, and Health, 
SuRGEON GEN., https://addiction.smgeongeneral.gov/executive-smmnary (last visited Sept. l 6, 2019) 
(stating that "only about 10 percent of people with a substance use disorder receive any type of 
specialty treatment"). 
71 Id 
72 TEDS, supra note 68. 
73 Austin Jones et al., Where Modes Treatment Are Available, 
HEALTHAFF. BLOG (Jan. 9, 2018), https://ww\:v.healthaffairs.org/do/10.1377/hblog20180104.835958/ 
full; see Ramin Mojtabai et al., Medication Opioid Use Disorders in Substance Use 
Treatment Facilities, 38 HEALTH AFF. 14, 17 (Jan. 2019), (stating that in 2016 only thirty-six percent 
of medical facilities offered any of the three medications approved by the FDA). 
74 Mojtabai, supra note 73, at 17. 
75 See Andersen, supra note 12 (describing a Louisville, Kentucky native's experience feeling like a 
"fraud" in a 12-step program because he was also prescribed suboxone). 
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C. Treatment Options 
In response to the OUD epidemic, researchers have extensively evaluated the 
effectiveness of available treatment methods. 76 Through this research, OUD has come to 
be seen as a "chronic medical disease" rather than an ongoing series of moral failures. 77 
There are currently three FDA approved medications for OUD: methadone, naltrexone, 
and buprenorphine.78 Each has proven effective, but the three differ in safety, side 
effects, ease of use, and risk of diversion.79 Additionally, the medications differ in who 
is authorized to prescribe or dispense them, and how difficult it is for patients to receive 
treatment with each medication. 80 
Naltrexone blocks the opioid receptors in the brain, but does not provide any relief for 
ongoing withdrawal symptoms.81 Patients must abstain from opioids for at least one 
week before starting naltrexone. 82 Since naltrexone is not a controlled substance, it can 
be prescribed by any licensed physician. 83 However, if patients stop taking the drug and 
start reusing opioids, their risk of a life-threatening overdose increases. 84 
Methadone can only be dispensed through licensed opioid treatment programs ("OTP"), 
which are extensively regulated. 85 For safety reasons, patients must visit these treatment 
centers daily and take the medication under supervision. 86 This treatment regimen often 
76 Definition of Addiction, AM. Soc'y OF ADDICTION MED. (Aug. 15, 2011), https://www.asam.org/ 
resomces/ definition-of-addiction. 
77 Id. For example, the American Society of Addiction Medicine (ASAM) states that addiction is "a 
treatable, chronic medical disease involving complex interactions among brain circuits, genetics, the 
environment, and an individual's life experiences. People with addiction use substances or engage 
in behaviors that become compulsive and often continue despite harmful consequences. Prevention 
efforts and treatment approaches for addiction are generally as successful as those for other chronic 
diseases." Id. 
78 Nora D. Volkow et al., A1edication-Assisted Therapies3;4Tackling the Opioid-Overdose Epidemic, 
370 N. ENGL. J. Mm, 2063, 2064-65 (2014). 
79 Id. at 2065; HaidenA. Huskamp et al., Coverage ofi\1edications that Treat Opioid Use Disorder 
and Opioidsfor Pain Management in Marketplace Plans, 2017, 56 MED. CARE 505, 506 (2018). 
80 Huskamp, supra note 79. 
81 Volkow, supra note 78, at 2065. 
82 Id. 
83 Naltrexone, SAMHSA, https://www.samhsa.gov/medication-assisted-treatment/treatment/ 
naltrexone (last visited Nov: 17, 2019). 
84 Id. (stating that "it is possible that the dosage of opioid that was previously used may have 'life-
threatening' consequences"). 
85 Huskamp, supra note 79; Oversight of Opioid Treatment Program (OTC) Accrediting Bodies, 
SAMHSA, https://www.samhsa.gov/medication-assisted-treatment/legislation-regulations-
guidelines/oversight (last visited Oct. 22, 2019) (explaining how SAMHSA obtained administrative 
responsibility over the use of opioid medications in maintenance and detoxification of substance 
abused disorders). 
86 Volkow, supra note 78, at 2065. SAMHSA has administrative responsibility over the use of 
opioid medications in maintenance and detoxification treatment of substance use disorders and has 
established procedmes for an entity to become an approved accrediting body. See Certification 
Opioid Treatment Programs (OTPs), SAMHSA, https://W\,rw.samhsa.gov/medication-assisted-
treatment/opioid-treatment-programs. 
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creates hardships for patients because it may interfere with their daily schedule, family, 
work, and other responsibilities. 87 The required monitoring may also be embarrassing 
and stigmatizing to patients. 88 
Finally, buprenorphine can be prescribed in an office-based setting, which does not 
interfere with patients' work and family schedules but can only be prescribed by 
practitioners who receive an authorization from the DEA. 89 Buprenorphine suppresses 
symptoms more effectively than methadone, while still allowing for once daily dosing. 90 
Currently, the standard of care for the treatment of OUD is extended maintenance on 
an opioid agonist.91 Because the medical profession played a role in the emergence 
of the recent opioid epidemic through aggressive management of pain, and because 
physicians play a central role in the treatment ofOUD, regulators have focused much of 
their efforts on regulating physicians.92 The regulatory framework governing physicians 
prescribing buprenorphine for OUD markedly departs from the typical regulation of 
the professional practice of medicine.93 In the area of OUD treatment, regulations 
have limited physician autonomy more than in any other area ofmedicine.94 Given the 
definition of OUD as a chronic medical disease, along with the strong research support 
for treatment with medication, preserving the physician-patient relationship model of 
care is particularly important. 95 
II. ANALYSIS 
A. The Current OUD "Treatment Gap" 
The National Survey of Substance Abuse Treatment Services (NSSATS) indicates that 
in 2016 over one million patients were treated at 15,000 substance abuse treatment 
facilities. 96 Today's OUD treatment environments include general hospitals, behavioral 
s7 Huskamp, supra note 79. 
88 Id. 
89 See supra notes 51-5 5 and accompanying text 
90 See Volkow, supra note 78, at 2065 (presenting a chart comparing the advantages, disadvantages, 
uses, and effects of methadone, buprenorphine, and naltrexone ). 
91 Andrew S. Huhn & Kelly E. Dunn, Why Aren 
78 J SUBSTANCE ABUSE TREATMENT 1, 2 (2017). Opioid agonists are drugs that activate the opioid 
receptors in the brain. What is this NAT'Li'l.LLIANCE OF ADVOC. FOR 
BuPRENORPHlNE TREATMENT, https://wv.w.naabt.org/faq_answers.cfm ?ID=5. 
92 See 
sarrih,;a. ~:ov;1m(:du;at1on--as:;1sted-treatn1enV kog15;Jatmn-regulatHJns-g1.11d(:Jrn es/spt:cia (describing 
limitations placed on physicians 
Treatment Act). 
the Controlled Substances Act and the Narcotic Addiction 
93 See supra notes 52-58 and accompanying text 
94 See supra notes 52-58 and text 
95 See supra notes 77-80 and accompanying text. 
96 Notably, although buprenorphine is considered the standard of care for OUD, only twenty-seven 
percent of the facilities provided that treatment regimen. National 
Treatment Services (N-SSAT;.,): 2016 Data on Substance Abuse Treatment Facilities, SAMHSA, at 
1-3, 24, https://www.sanilisa.gov/ data/sites/ default/files/20 l 6 _NSSATS. pdf (stating that the survey 
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health hospitals, recovery centers, and opioid treatment programs ("OTP").97 Two major 
legal issues affecting these environments are unfair business practices and a lack of 
informed consent.98 
False advertising is a persisting unfair business practice in some facilities. For example, 
Richard Taite, the owner of Cliffside Malibu, a "world class luxury drug and alcohol 
treatment center," advertises that his center provides an evidence-based model that offers 
the "very best [treatment] science has to offer."99 In Taite's publications in Psychology 
Today, he states that using MAT is simply trading one drug for another, and he asserts 
that doctors who prescribe medications for OUD are trying to "keep people dependent 
on drugs" for financial reasons, claiming that participating in an abstinence in-patient 
treatment program for over ninety days is the best opportunity for long-term recovery. 100 
Taite also suggests that it is unsafe to leave children with anyone being treated by MAT, 
but these statements contradict outcomes-based research and are detrimental to the 
provider-ODD patient relationship. 101 
Further, many existing facilities deviate from established standards for informed 
consent. 102 The treatment of OUD with Office-Based Opioid Treatment ("OBOT") using 
smvey, outpatient treatment was offered by 82% of facilities, and 91 % of the patients received that 
treatment. Residential treatment was offered by 24% of facilities and received by 1 % of patients. 
Inpatient was offered by 5% of facilities and received by 1 % of patients. Eighty-fom percent of 
all facilities had websites that provide information about a facility's substance abuse treatment 
programs, and sixty percent of all facilities provided outreach to persons in the community needing 
treatment) [hereinafter N-SSATS]. 
97 Id 
98 See generally infra notes 99-103 and accompanying text. 
99 See How We Treat, CLIFFSIDE MALIBU, https://www.cliffsidemalibu.com/how-we-treat/ (last 
visited Sept 16, 2019). The Cliffside Malibu seeks the best evidence-based counseling, but the 
previous attacks on the use of MAT are clear. This Article proposes that in the same way that 
those supporting MAT should not say psychosocial counseling should not be used, a supporter 
of abstinence-based treatment oversteps when stating that MAT should not be used. The decision 
should ultimately lie with the patient 
100 Richard Taite, Appropriate Uses for Suboxone and Subutex Therapies, PSYCHOLOGY TODAY (Mar. 
18, 2013), https://www.psychologytoday.com/us/blog/ending-addiction-good/201303/appropriate-
uses-suboxone-and-subutex-therapies (stating that these medications "keep the individual just 
high enough not to have to deal with their underlying pain or trauma and maintain some ability 
to function in the world."); Richard Taite, The Move Away From Abstinence Based Addiction 
Treatment, PSYCHOLOGY TODAY (Jan. 07, 2015), https://www.psychologytoday.com/us/blog/ending-
addiction-good/20150 lithe-move-away-abstinence-based-addiction-treatment (asserting that the 
doctors and the pharmaceutical industry push these medications solely for financial reasons). 
101 Richard Taite, Suboxone and Methadone Maintenance Therapy: As a Father, My Heart Belongs 
to My Children, PSYCHOLOGY TODAY (Nov. 3, 2015), https://www.psychologytoday.com/hk/blog/ 
ending-addiction-good/201511/suboxone-and-methadone-maintenance-therapy?amp; see generally 
Lama B. Monico et aL, Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, 
Compatibilities and Patient Outcomes, 57 l SuBSTANCE ABUSE TREATMENT 89, 89-95 (2015) 
(explaining the antagonistic effects of abstinence in comparison with MAT). 
102 See generally Azar, supra note 13 (stating "[g]iven what we know, and given the scale of this 
epidemic, having just one-third of treatment programs offer the most effective intervention for 
opioid addiction is simply unacceptable."). 
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buprenorphine is effective, but only about a third of facilities offer such treatment. 103 
This Article argues that the source of this shortage is multifactorial and can be best 
understood by reviewing the effect of these factors on the physician-ODD patient 
relationship. While specific solutions have been proposed to address the treatment gap, 104 
this Article focuses on legal principles surrounding the doctor-patient relationship. If 
these legal principles are used properly in the care of OUD patients, a wider variety of 
effective treatment options will be available. 
B. The Doctor-OUD Patient Relationship and the Role of Informed Consent 
In Cruzan v. Director, Missouri Dept. of Health, 105 the Supreme Court described the 
doctrine of informed consent as "the [sacred] right of every individual to the possession 
and control of his own person," which ensures that "every human being of adult years 
and sound mind has a right to determine what shall be done with his own body."106 This 
right to the "possession and control" of one's own person was first recognized by the 
Supreme Court in 1891 in a negligence action against a railroad company that arose 
from an injury caused by a falling train bed. 107 In the medical context, failure to obtain 
informed consent is viewed as a breach of a professional duty. 108 
The decision in Canterbury v. Spence109 replaced the "professional practice" standard 
in medical malpractice cases with the "reasonable person" standard, which led to an 
increase in litigation and to an increase in the number of physicians who were willing 
to testify against each other in court. 110 In this case, a nineteen-year-old patient sued 
his physician after a routine back surgery left his legs permanently paralyzed. 111 Under 
103 Id. 
104 See, e.g., Health: Hub VERMONT, http://blueprintforhealth.vermont.gov/ 
about-blueprint/hub-and-spoke (last visited Oct. 22, 2019) (discussing "Hub and "Vermont's 
system of l'v1AT, which supports people in recovery from OUD); Daniel f' Alford, Collaborative 
Care in Primary Care Using Five-Year Experience, 
JAJ'v1A Network (Mar. 14, 2011), https://jamanetwork.com/journals/jamaintemalmedicine/ 
fullarticle/226781 a program started at Boston Medical Center which used a !hree-stage 
model of collaborative care, between nurse care managers and physicians, to treat 
addicted to opioids); See Treatment, BALTIMORE CITY HEALTH DEP'T, h1tps://heal1h. 
baltimorecity.gov/opioid-addiction-treatment (last visited Oct. 22, 2019) Baltimore 
Health Department's use of a combination of MAT, psychosocial support, and wraparound social 
services). 
105 497 U.S. 261, 269 (1990). 
l06 Cruzan, 497 U.S. at 269 
129-130 (N.Y. 1914)). 
to7 Union Pacific R. Co. v. Botsford, 141 U.S. 250, 251 (1891). 
IOS See Paula Walter, The Doctrine Consent: To or Not to , 71 ST. JoHN 
L. REv. 543, 558 (1997) (explaining that injuries claimed in lack of consent actions arise from a 
breach of his or her duty to adequately inform the patient). 
109 464 F.2d 777 (D.C. Cir. 1972). 
110 Id. at 780. Sam Roberts, Jerry Whose Led to Consent Laws, is 
Dead at 78, NY TIMES (May 16, 2017). https://www.nytimes.com/2017 /05/16/us/jerry-canterbury-
medical-consent-paralysis.html. 
111 464 F.2d at 777-80; Roberts, supra note 110. 
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Canterbury, "true consent to what happens to one's self is the informed exercise of a 
choice, and that entails an opportunity to evaluate knowledgeably the options available 
and the risks attendant upon each." 112 After this case, the standard for informed consent 
considers what information was "material to the patient's decision," not what the 
"medical custom in the community would demand."113 
If applied correctly in the OUD context, the patient-oriented standard of disclosure 
expressed in Canterbury requires a physician to discuss the effectiveness of both an 
abstinence program and buprenorphine treatment with his patient. 114 The average 
patient has little or no medical knowledge, so he typically must rely on his doctor to help 
him make the best medical decision. rn This reliance creates obligations for the doctor 
associated with "fiducial qualities," which include the "duty to reveal to the patient that 
which in his best interests it is important that he should know."116 
A physician should inform a patient not only of the risks involved with the proposed 
treatment, but also of any alternatives that might offer greater benefits than the current 
treatment. 117 For some patients, B-MAT promises greater results than the abstinence 
model of treatment, which "has one of the worst success rates in all of medicine."118 
Therefore, doctors should inform each patient about both the risks of abstinence 
treatment and about more effective treatment alternatives such as B-MAT. 119 Using the 
reasonable patient standard of informed consent shifts the doctor's focus from playing 
the role of a paternalistic provider, controlling the care of an untrustworthy and morally 
flawed patient, to a patient-centered approach that respects the patient's autonomy and 
his right to self-determination. 120 While OUD patients have become largely accustomed 
to being "beaten down" and treated as moral failures, it is vital that these patients are 
treated with respect and afforded the opportunity to make decisions. 121 
While there is a concern that the average patient will be unable to understand his 
condition and treatment options, Canterbury insists that only "the exceptional patient" 
cannot gain at least a basic understanding of his condition. 122 While the physician's 
required disclosures need not amount to a "medical education," they must inform the 
112 464 F2d at 780. 
113 Id at 786-87. 
114 Id 
115 Id at 780. 
117 Id at 781. 
118 
885 (1991). 
121 Heimer, supra note 15, at 548. 
122 464 F.2d at 782 n. 27. 
under a to disclose all risks 
an informed medical decision). 
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patient about available alternative therapies, discuss the results that the patient can expect 
to achieve, explain the risks that may ensue from a particular treatment, and highlight 
the potential consequences of receiving no treatment."123 Because many OUD patients 
are desperate by the time they obtain treatment, a doctor must take extra precautions to 
properly inform these patients. 124 Even though many OUD patients are suffering from 
severe withdrawal symptoms such as nausea, vomiting, and chills, they are nonetheless 
capable of giving informed consent. 125 
To establish the ideal doctor-patient relationship, both the doctor and the patient must 
understand the context of the patient's condition. 126 For example, there is a significant 
difference in appropriate informed consent for the treatment of a disorder that only the 
physician can clearly and fully understand, and a condition for which the treatment 
options and studies detailing the outcomes are readily available to patients. 127 Fortunately, 
OUD treatments fall in the latter category because patients can easily obtain an accurate 
comparison of available treatments. 128 While it may be difficult for some patients to 
understand certain technical aspects of OUD treatments, such as the makeup of a 
medication or how the medication interacts with the body, most patients can understand 
the statistical likelihood of success and the steps that each treatment option involves. 129 
OUD treatment is both effective and addresses the treatment gap because physicians can 
disseminate information about the treatment to the patient. 130 Patients with an existing 
doctor-patient relationship can extend their care to include OUD by the same physician in 
a familiar environment. 131 Likewise, patients creating a new doctor-patient relationship 
can receive treatment by one provider both for their primary care and for their OUD 
123 Id.; see also Stinnett v. Price, 446 S.W2d 893 (Tex. App. 1969) (finding that a doctor telling 
a patient that a was more serious than the patient's previous procedure and that the 
procedure could cause a stroke was sufficient to info1med consent). 
124 See 464 F2d at 782. These precautions will be addressed through tailored 
informed consent requirements in this Article's Resolution. 
125 Edmund Henden, Heroin Addiction and Choice: The Case Consent, 27 
BIOETHICS 395, 395-401 (2013). 
126 See Susan Dorr Goold & Mack Lipkin, Jr, The 
141 GEN. INTERNAL MED. S26, S29 (1999) (stating that physicians 
is impmiant for a strong relationship). 
127 Id. (stating that informed consent requires the doctor to disclose information necessary for the 
to evaluate available 
128 See e.g., N-SSATS, supra note 96 (comparing information on mechanisms, phases or treatment, 
adverse side-effects, and of OUD treatments). 
129 Canterbury, 464 F2d at 782. 
u11u;t;-·nu,,<:u Opioid Use Disorder Treatment: A H:,,,.,,r,,nr" 
rn•1;su:11111s NAT. INST. ON DRUG ABUSE, http://vvwwfamilydocs.org/wp-content/uploads/20 l 9/06/ 
visited Oct 7, 2019) (reporting that Office-Based 
Opioid Treatment works for 50-80 percent of patients) [hereinafter NIDA]. 
131 See Leslie R Martin et aL, The '-""'m"·""" am:re1ice 3 THERAPEUTICS & CLINICAL RISK 
MGMT. 189, 192-93 (2005) that between the doctor and improves 
outcomes). 
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needs, as long as the provider is qualified to prescribe buprenorphine. 132 Strengthening 
these supportive relationships will help overcome patient resistance to treatment. 
C. The Role of Hospitals and Treatment Centers in Providing Institutional 
Support to Doctors and Information to OUD Patients 
A treatment center should ensure that its service delivery is aligned with the best 
treatment options for the community and that its providers inform patients of the 
alternative treatments available and the risks and benefits of each treatment. 133 As the 
court noted in Darling v. Charleston Community Memorial Hospital, 134 the patient 
who enters a hospital for treatment expects that the hospital will attempt to cure his 
condition, not that its employees will "act on their own responsibility."135 Similarly, in 
Thompson v. Nason Hospital, 136 a case in which a patient recovered against a hospital 
because of the hospital employees' negligent acts, the court held that a hospital could be 
held liable for corporate liability if it "fails to uphold the proper standard of care owed 
[to its] patient."137 Under Thompson, a hospital has a duty to maintain safe facilities, 
employ and retain competent physicians, oversee physicians who practice medicine in 
the hospital, and formulate, adopt, and enforce adequate rules. 138 
Applying Thompson to the OUD epidemic, facilities that fail to oversee their providers 
or to "formulate, adopt, and enforce adequate rules" would be subject to legal 
ramifications. 139 Treatment facilities should not be able to ignore current research-backed 
best practices. Current prescription policy does not provide resources or institutional 
support for providers who want to prescribe MAT. 140 This lack of support for MAT 
providers is a noted reason for doctors not seeking to become authorized to provide 
MAT, or becoming authorized but not fully utilizing the authorization by prescribing to 
fewer patients than permitted. 141 
Research shows that educating doctors and patients improves treatment outcomes; 
therefore, institutional support for OUD treatment facilities is crucial in improving 
patients' chances of successful rehabilitation. 142 Specific training regarding medication 
132 ld 
133 See Magana v. Elie, 439 N.E.2d 1319, 1321 
includes the to "conform to the 
apparent risk"). 
134 211N.E.2d253 1965). 
135 Id. at 257. 





140 See uaua1..,..,, supra note 38, S230. 
141 Id. 
142 See Amanda l Abraham et al., '-"utm01;wr 
App. Ct 1982) that the 
standard of reasonable conduct in 
ueveri•ae11ce. 70 l SrnD. ALCOHOL & DRUGS 628, 628 (2009) 
ofa 
of the 
education have effective 
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use and observation of that use leads to significant changes in counselors' perceptions 
of the effectiveness and acceptability of the medications available for the treatment of 
substance use disorders. 143 
The authors of Using Medication-Assisted Treatment for Substance Use Disorders: 
Evidence of Barriers and Facilitators of Implementation note that a significant 
number of physicians currently involved with treatment programs are not prescribing 
buprenorphine. 144 According to them, of those with physician access, forty-nine percent 
among private sector programs and sixty-seven percent among public programs did 
not prescribe buprenorphine. 145 Additionally, the authors note that the public knows 
very little about buprenorphine and other substance use disorder medications. 146 They 
hypothesize that if more information was given to the public regarding buprenorphine, 
its demand would also increase, thus increasing buprenorphine's availability at public 
treatment centers. 147 
As mainstream facilities, such as Massachusetts General Hospital, Johns Hopkins, 
and Yale New Haven Hospital, 148 start implementing MAT, other hospitals will likely 
follow. 149 Because of the prestige of these hospitals, patients, the general public, and 
other hospitals are likely to learn about the procedures and practices these facilities 
implement. 150 As more hospitals and facilities integrate and implement these new 
procedures that larger hospitals have had success with, the standards of communities 
across the country will begin to change. 151 The pressure to follow community standards 
and the demand for optimal treatment will make it increasingly difficult for facilities to 
continue to promote outdated models of treatment. 
143 ( di:icu:ssJitg a survey shmving that "those who had been exposed to training 
"IS"u.""'"""Y more to rate it as effective and as acceptable for their 
144 Paul M. Roman et aL, 
Evidence 
Huhn & Dunn, supra note 91, at 2. 
145 Roman, supra note 144, at 588. 
146 Id 
147 Id 
Substance Use Disorders: 
otlmD'fenzentatzon. 36 ArnJ1cnvE BEHAVIORS 584, 588(2011 ); 
148 Martha Bebinger, MGH Becomes 1st Mass. ER to 
Path to Recovery, CoMMONHEALTI-I (Mar. 7, 2018), htttr//,cxm1w 
mgh-addiction-medication. 
149 Id, see the JmJNs HOPKINS CTR. INNOVATIVE MED., 
http://vv\'ITW.hopkinscim org/breakthrough/holiday-2017 /breaking-cycle-opioid-dependence; 
,Juurn1uuga, This ER Treats on Demand That:\' Very Rare, NY TIMES (Aug. 18, 
D'Onofrio et aL, Emergency lJepa1·tm,ent-lm'tza1 
uever1'l1e1u;e. 313 JAMA NETWORK 163 6, 163 6-44 (2015) that testing this MAT treatment 
results but needs to be before wide usage). 
15o Bebinger, supra note 148. 
151 Id 
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D. Unfair Business Practices and False Advertising by OUD Treatment Facilities 
Unfair business practices used by OUD treatment facilities also contribute to the 
treatment gap. 152 There are many documented accusations alleging that OUD treatment 
facilities make false claims about their services. 153 Since the FTC has the authority to 
prohibit "unfair or deceptive acts or practices," it also has a responsibility to protect 
patients from unfair business practices that jeopardize public health. 154 The agency has 
already taken action by issuing warning letters to multiple marketers and distributors 
who were making false claims about their opioid cessation products. 155 Additionally, the 
FTC has worked with SAMHSA to better inform patients who were misguided by false 
claims about MAT, 156and the agency provides other resources to help those in need get 
the "right" help for addiction and withdrawal. 157 
States also have the power to regulate physician advertising that is "false, fraudulent, 
deceptive ... misleading," or that "tends to injure the public by lowering or demoralizing 
professional standards."158 Amid the current opioid epidemic, states have a legitimate 
interest in promoting the public health and safety of their residents; thus, states can 
regulate misleading medical advertising to protect their residents from suffering health 
consequences as a result of such advertisements. 159 
Similarly, medical associations play a role in ensuring that physicians do not mislead or 
deceive patients. The American Medical Association (AMA) provides ethical standards 
for physician advertising and states that advertising should be "explicitly and implicitly 
truthful and not misleading."16° Further, the American Osteopathic Association warns 
against deceptive statements that are "likely to lead a patient to a misinformed choice 
152 See e.g., Andersen, supra note 12 (reporting that certain treatment facilities claim to treat OUD 
addiction without the use of MAT prescriptions). 
153 E.g., Tennessee Substance Abuse Treatment to Resolve False Claims Act 




156 the or Withdrawal, FTC: CONSUMER INFO. (Jan. 
24, 2018) https://www.consumer.ftc.gov/articles/0223-getting-right-help-opioid-dependence-or-
that receiving FDA-approved medication-assisted treatment cut their 
"'·"-'muing to SAMHSA"). 
157 Id. 
158 61 AM. JuR. 2D Yff1mr·1m1., ,)1~rf!em1s. and other Healers§ 13 (1981). 
159 epidemic and the projected increase of 
160 AMA Code 
medical-ethics. 
AM. MED. Ass'N, 
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and unjustified expectations."161 OUD patients are accustomed to being beaten down, 
and they may be desperate for any type of treatment, making them more vulnerable and 
susceptible to misleading advertisements or statements. 162 Therefore, OUD providers 
should exercise extra care when making statements or advertising treatment outcomes, 
and should be held accountable for the impacts of such statements. 
Similarly, medical boards should ensure that providers are informing their patients of 
all available treatments, especially those with lifesaving potential. In its Model Policy 
for Opioid Treatment, the Federation of State Medical Boards recognized that treatment 
with medication should be considered for every OUD patient. 163 Because of the current 
treatment gap and the projected increase in deaths from OUD, there is a need for 
informed consent that takes the dynamics of an OUD patient into consideration. 164 
III. BEST PRACTICES FOR OBTAINING INFORMED CONSENT 
FROM OUD PATIENTS 
As standards for informed consent and the physician-patient relationship have evolved, 
the current OUD treatment dynamic clearly demonstrates the ongoing conflict between 
physician paternalism and patient autonomy. 165 The treatment of OUD patients with 
B-MAT represents a unique test case for informed consent because of the potential 
therapeutic value it may bring to a patient group that has historically been discriminated 
against. 166 In this setting, a mutual provider-patient decision, which once seemed 
inconceivable, may now be a possible end goal of the use of informed consent to treat 
the OUD patient. 167 
161 AOA Interprets Code of Ethics, AM. OSTEOPATHIC Ass'N, https://osteopathic.org/about/leadership/ 
aoa-govemance-documents/ code-of-ethics/ aoa-interprets-sections-of-code-of-ethics-1996-present. 
162 Jake Harper, Addiction Clinics Market Unproven Treatment to Desperate Patients, ABC NEWS 
(Aug. 27, 2019), https://abcnews.go.com/Health/addiction-clinics-market-unproven-treatments-
desperate-patients/story?id=65203013. 
163 See Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical 
FED'N STATE MED. BOARDS 7 (2013), http://www.fsmb.org/siteassets/advocacy/policies/model-policy-
on-data-2000-and-treatment-of-opioid-addiction-in-the-medical-office. pdf (stating that under this 
model, providers are not required to inform patients of MAT options) [hereinafter Model Policy]. 
164 See Chen, supra note 19, at 8 (predicting that the annual number of opioid overdose fatalities in 
the United States will reach over eighty-one thousand by 2025). 
165 See Robert Walker et al., Consent to Undergo Treatment for Substance Abuse: 
A Recommended Approach, 29 J. SuBSTANCE ABUSE TREATMENT 241, 246 (2015) (attributing the 
difficulty to "a lack of clear and distinct substance abuse treatment procedures"). The extensive 
outcomes research in this area helps address the historic dilemma of balancing patient autonomy 
against physician decision-making. Research results in this area help guide both patients and care 
providers. 
166 Id. 
167 Salgo v. Leland Stanford Jr. Univ. Bd. of Trustees, 317 P2d 170 (Cal. Ct. App. 1957). Justice 
Bray, writing for the California District Court of Appeals in his Salgo v. Leland Jr., 
opinion used both the term "full disclosure" and the term "discretion" 
in the same sentence describing informed consent under the category of "duty to disclose." ld. 
at 181. Subsequently, Katz has pointed out that this combination is very difficult and that the 
central problem of true informed consent is the conflict between "patient self-determination" and 
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Because of the life-and-death ramifications of the current treatment environment, 168 a 
clear definition of informed consent is important for the development of the provider-
OUD patient relationship. Perhaps a tailored definition would later become applicable to 
other areas of medicine, but as Jay Katz has suggested, informed consent could contain 
different specifications for different categories of cases. 169 
A. Scope and Timing 
These proposed best practices should be implemented whenever a patient enters care 
for OUD. Anytime that a prospective OUD patient seeks advice or treatment from a 
medical provider, and the provider in turn agrees to render such advice or treatment, 
the provider-ODD patient relationship is created. 170 With the existence of such a 
relationship, informed consent for the provider-ODD patient relationship is applicable. 
The scope of application for these best practices should include, but is not limited to, 
the four points where OUD patients typically enter care: primary care providers (such as 
family practice providers, internists, and gynecologists);171 behavioral health facilities 
(such as Universal Health Services ("UHS") and mental health units within general 
hospitals);172 commercial addiction treatment centers (such as Passages Malibu);173 and 
emergency rooms and urgent care centers. 174 
B. The Treatment Agreement Requirement 
At the outset of the provider-ODD patient relationship, the OUD patient should receive 
a written contract ("treatment agreement") that outlines the available treatments 
for OUD and clarifies the patient's right to be informed about each of the available 
treatments before deciding whether to be treated. 175 Contracts are not a foreign concept 
in the treatment of OUD. 176 Unfortunately, OUD patients typically do not have the 
REV. 137, 138 (1977). 
168 See Chen, supra note 19 (concluding that m1der the status quo, the munber of opioid 
overdose deaths is projected to continue to increase). 
169 See Katz, supra note 167, at 173. 
171 Primary Care, AM. AcAD. FAM. PHYSICIANS, https://v1rww.aafp.org/about/policies/all/primary-
care.html visited Sept 16, 2019). 
172 See Behavioral Health, UNIVERSAL HEALTH SERV., https://wwvv.uhsinc.com/about-uhs/ 
behavioral-health (last visited Sept 16, 2019) (providing an overview of universal health services). 
173 PAS SAGES MALIBU, https://passagesmalibu.com/philosophy/the-four-causes-of-
visited Nov. 2, 2019). 
174 supra note 149. 
175 See TIP 63: Use Disorder Part 5: Resources Related to Medications 
Use Healthcare and Addiction Patients, and 
Families, SAMSHA, 52-53, The first 
two statements in the treatment agreement ensure that the risks and benefits of alternate 
treatments are explained to the Id. 
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opportunity to analyze treatment options at the outset, but instead receive a written 
contract explaining potential side effects of the medication only after choosing to pursue 
B-MAT. 177 Use of a contract at the formation of the provider-ODD patient relationship 
narrows the treatment gap by informing patients of all alternative options for OUD 
treatment and places the patient in the position to make an informed decision. 
In the same way that patients are informed about the risk of death from mixing 
buprenorphine with benzodiazepines, the need for additional counseling, and the lack of 
a fixed time for the completion of treatment, they should be made aware of the potential 
positive outcomes of treatment with buprenorphine. 178 This disclosure should be made 
at the formation of the relationship, simultaneously with the disclosure of potential 
outcomes of alternative treatment methods. 179 The distribution and execution of a 
treatment agreement at the beginning of the relationship allows the patient to see the 
"big picture" and to choose a path based on his own personal preferences and needs. 180 
Before deciding on a treatment method, the patient should sign the treatment agreement, 
which should state that the provider has informed her of the associated risks and possible 
alternative treatment options. 181 The treatment agreement should specifically mention 
those alternative options and include a description of the available outcome-based 
research and government funded resources. 182 
C. Methods of Informing Patients of Available Treatment Alternatives 
The provider should disclose "medically reasonable alternative" treatments183 by either 
discussing the specific results of outcome-based research and the government funded 
resources that are available, or providing those materials for the patient to read on his 
own. 184 If the provider chooses to provide the materials to the patient, the provider should 
offer to discuss any questions that the patient has about the material.185 This approach 
also allows the patient an opportunity to reflect and make an informed decision. 186 
Providers should be aware of potential litigation that they could be subject to if they 
fail to inform patients of medication-assisted treatment options. 187 Although settled 
outside of court, Osheroff v. Chestnut Lodge, 188 a case in which a provider relied solely 
177 Id 
178 Jd 
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183 Matthies v. Mastromonaco, 733 A2d 456, 457, 457 (N.J 1999). 
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on psychotherapy in treating a patient suffering from depression, invited an influx 
of malpractice claims on the basis of providing treatment without medication when 
medication was available. 189 Treatment facilities should ensure that providers inform 
patients about available medications even if the facility does not offer medication-
assisted treatment. Providers should be ready to inform a patient when the patient can 
receive medication-assisted treatment and of alternate locations that offer MAT. 
D. The Decision-Making Process 
i. The Patient-Centered Approach 
A "patient-centered approach," in which the patient is an active participant, is critical 
to the provider-ODD patient relationship. 190 While providers often adopt a paternalistic 
approach with OUD patients, due to preconceived notions that the patient has a history 
of poor judgement, the best treatment for a patient requires respecting the patient's 
autonomy and freedom by allowing the patient to choose from treatment options as 
shown through the tenets of motivational interviewing. 191 A patient with a broken leg, 
for example, may not need to feel central in his treatment decision-making process%he 
would just prefer the best available treatment. However, with the unique treatment of 
OUD, the patient-centered approach may be instrumental. Under this approach, "the 
physician tries to enter the patient's world, to see the illness through the patient's eyes." 192 
Physicians should adopt motivational interviewing techniques to help facilitate the 
use of informed consent. Through motivational interviewing, an empathetic, "client-
centered counseling style for eliciting behavior change," patients play an active role in 
their healing. 193 One of the basic principles of motivational interviewing is acceptance, 
which involves "honoring and respecting each person's autonomy, their irrevocable right 
and capacity of self-direction."194 Providers who incorporate motivational interviewing 
into their practice should inform the patient of the available treatment options, place the 
patient in the decision-making position, and listen to and empathize with him so that he 
has the best chance to get the most effective treatment. 
189 Id 
190 See Ronald M. & Richard L. Street, The Values and Value 
Care, 9 ANNALS FAM. MED. 100, 100-03 (2011) that 
to encourage them to 
modifications to prevent disease and alleviate their symptoms). 
1r1.;1ns1orniea Clinical Method, in Stewart M. & Roter D., 
COMMUNICATING WITH MEDICAL PATIENTS 111 (1989). 
193 Rollnick and William R. Miller, What is Motivational 23 BEHAVIORAL 
AND COGN!T!VE PSYCHOTHERAPY, 325-34 (1995), 1017/S135246580001643X. 
194 MILLER & Rau.NICK, supra note 191, at 18. 
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ii. Elimination of Bias 
What a provider believes is the best treatment method should be irrelevant to the 
determination of which alternatives should be disclosed. The provider should, in 
an unbiased fashion, discuss treatment alternatives based on available research. 195 
Informed consent has the potential to transform the doctor-OUD patient relationship 
because of the therapeutic value that patients may receive from being closely involved 
in their own decision-making. 196 Informed consent "forces the therapist to examine his 
biases in regard to valuing his system over other available systems," which causes the 
therapist to "join the patient in the major therapeutic task of searching out distortions and 
misperceptions."197 This "mutual participation" has been shown to curb the tendency 
toward a "one-size-fits-all treatment."198 
iii. Providers Must Offer Advice, Not Make the Patients Decision 
The provider must use his knowledge of the patient's situation to assist the patient in 
making an informed decision, but the provider should be careful not to make the choice 
for the patient. 199 Through motivational interviewing and a strong OUD provider-
patient relationship, the provider learns information unique to the patient.200 Using 
this information, the provider can advise the patient without steering him or effectively 
making a decision for him.201 The provider is in the best position to weigh the risks and 
benefits because of the provider's knowledge about the patient's situation.202 
iv. No Therapeutic Privilege Not to Disclose Alternative Treatments 
The "therapeutic privilege not to disclose"203 should not be used with the treatment of 
OUD patients because the disclosure of options and the patient decision are significant 
Use Disorder Part 3: Use 
r-r1""'''s11mo1s SAMSHA, 9, https://store.samhsa.gov/system/files/sma18-
196 See Gerald Epstein, Consent and the 6 J. PsYCHIAIRY & L. 359, 
361 (1978) (asserting that discussing the risks and alternatives of treatment options with a patient 
acknowledges that he or she is of making appropriate decisions and thus "promotes an 
important shift in focus") . 
197 Id. at 362. 
Lu.um<:111·i~ 11•rn•mn1u1' DRuGREHAB.COM (June 4, 2018), 
1tnu1m,nr,rh c1~rn1tre·atfi7e~1t1t1mes-ot-tfier1'WV (noting that therapy is not a one-size-fits-all process 
because different approaches are often effective for different patients). 
199 See Matthies v. Mastromonaco, 733 A.2d 456, 462-63 (N.J. 1999) (stating that "[p]hysicians 
their values on their nor substitute their level of risk aversion for that of 
200 See MILLER & RoLLNJCK, supra note 191. 
20l Matthies, 733 A.2d at 462. 
202 See Walls v. Alpharma USPD, Inc., 887 So. 2d 881, 883 (Ala. 2004) (describing the doctor as 
a "learned intermediary" between the patient and the pharmacy because of the doctor's medical 
JU!l1w 1cmoc and understanding of his 
203 See Matthew Wynia, AMA J ETHICS 2004), https:// 
journalofethics.ama-assn.org/article/invoking-therapeutic-privilege/2004-02 (stating that "[t] 
herapeutic privilege is an exemption from informed consent guidelines and is, most would say, a 
frank exercise of paternalism. The Al\1A Code says that physicians may withhold 
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components of a recognized treatment method (e.g. motivational interviewing) for the 
OUD patient.204 Additionally, unlike many illnesses, treatment information is readily 
available in patient-readable formats through sources such as the HHS and SAMHSA 
(e.g., Treatment Improvement Protocol 63 ("TIP 63"), a document that reviews the use 
of FDA approved medications used to treat opioid use disorder).205 When a potentially 
lifesaving decision is at hand, the importance of the decision likely outweighs any reason 
to forego full discussion of alternative treatments. 
v. Mutual Decision-Making and Participation 
The struggle between autonomy and paternalism should be met with mutual decision-
making, which may not be possible in some areas ofmedicine.206 In the OUD context, 
research provides a clear picture of available alternatives, and a doctor should effectively 
communicate those alternatives.207 Providers should build an environment in which true 
decision-making can occur and the doctor's expertise is valued and weighed, but the 
patient holds the ultimate decision-making authority. 
Ideally, the provider and patient assess the likelihood of success together and mutually 
decide the best course oftreatment.208 Katz identified several factors as impediments to 
a patient's self-determination, two of which include the doctor's valuable time and the 
patient's limited medical knowledge.209 These two problems can be alleviated through 
the distribution of materials that are easy to understand that the patient can read on his 
own time. 
Instead of using short-term objective management, the provider-0 UD patient relationship 
requires communication of the patient's feelings and a discussion of his triggers so 
that the physician can better understand the patient's motivations for treatment.210 To 
facilitate the formation of a trusting provider-patient relationship, a provider should, 
when possible, learn about the patient's background to offer optimal advice about a full 
treatment plan.211 A comprehensive plan may incorporate recommendations on how to 
information about a or treatment when it would pose a serious 
µ>\'u1rnug1La1 threat, so serious a threat as to be contraindicated. But, the Code 
because a thinks 1he information, if 
needed treatment Competent retain the to 
refuse treatment and must be 
decisions about consent or refusal."). 
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avoid triggering situations, or advice to seek outside counseling when doing so would 
benefit the patient.212 
A joint provider-patient decision is especially important in the treatment of the ODD 
patient because of ODD's classification as a chronic condition.213 The patient's active 
participation in his own care is essential for successful treatment, as daily medicines 
and frequent counseling are usually required.214 This unique provider-ODD patient 
relationship contrasts significantly with the short-term management of such emergency 
events as cardiac arrest or trauma.215 
vi. Honest Communication 
A strong provider-ODD patient relationship encourages patients to be honest and 
disclose to the physician when they fail to meet the treatment guidelines. The provider 
will be in the best position to detect the patient's failure and help the patient take 
appropriate steps to move forward with the treatment.216 Because of the nature of the 
relationship, a patient trusts that his provider has his best interests in mind and he feels 
more comfortable disclosing sensitive information, even when the information may 
elicit negative consequences.217 
vii. "Reasonable Patient" and "Specific Patient" Standards 
A provider should tell an ODD patient all information that a reasonable patient would 
consider important in making a treatment decision and information that the provider 
knows that the specific patient would consider important.218 However, a patient has the 
right to choose any treatment option, including no treatment at all. 219 While it seems that 
requiring "truly informative" informed consent closes the treatment gap, a provider's 
respect for patient autonomy allows for patients to decide not to accept treatment even 
when fully informed.220 
Patients cannot have autonomy when they are uninformed. Katz argues that the 
reasonable patient standard may "abrogate the very right at issue in cases of informed 
consent," which he alleges is "the right of the individual choice;" however, the reasonable 
patient standard is used to convince providers to thoroughly inform patients because 
providers are bound to inform patients of all information that a reasonable patient 
would find important in making a treatment decision.221 A reasonable patient likely 
finds information about the most successful treatment for a life-threatening condition 
Use Disorder, supra note 205 
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important in making a treatment decision.222 Further, if a provider has reason to believe 
that a specific patient would find the information important in making a decision, the 
provider must also inform that patient of such information.223 This standard forces 
providers to think through the eyes of the patient and encourages the provider to develop 
an understanding of the patient's perspective. 
E. Business Practices, Advertising, and Facility Responsibility 
i. Extension of Liability to Facilities 
Informed consent requirements extend to hospitals and treatment centers.224 To the 
extent that false advertising and unfair business practices still exist, providers should 
be aware of the role that states, medical associations, and government agencies play 
in regulating false or misleading statements about the effectiveness of OUD treatment 
methods.225 Facilities must play an active role in promoting the best treatment options 
through the distribution of accurate and non-deceptive materials.226 
ii. Disclosure of Treatments Not Offered at the Facility 
As community standards improve, businesses and facilities should implement the 
treatments that have proved most effective through outcomes research. To the extent 
that the facility is unable to implement those treatments, the providers at the facility are 
obligated to inform patients of the effectiveness of the alternate treatments not offered at 
that facility and allow and encourage the patient to consider the possibility of receiving 
that treatment elsewhere. 227 
iii. Scope of Application 
Informed consent should apply to non-physician providers in the OUD setting. It is 
understood that OUD treatment involves not only medication, but also some sort of 
counseling in many cases.228 Further, for prescribers to receive authorization they must 
attest that they have access to counseling resources.229 Often, counseling resources will 
occur through a prescriber's referral, and such resources will be provided by outside 
psychologists, social workers, or other providers.230 Because of the important role of 
222 464 F2d at 782. 
223 Id. 
Keel v. St. Elizabeth Medical Center, 842 S.W2d 860, 861-62 (Ky. 1992) 
KRS 304.40-320, "health care have a 
See supra notes 160-161 and acc:ompar1vm 
226 See supra notes 160--161 and acc:ornpar1ym 
TIP 63, supra note 184, at 17-18. 
228 TIP 63: Use Disorder Part 
Counselors with Clients and Healthcare 
229 30 JOO Patient Limit, supra note 9 to refer 
addiction treatment for ~nrmwm~t.e 
230 Id; see also ELYN R. SAKS & SHAHROKH GOLSHAN, INFORMED CONSENT TO PSYCHOANALYSIS: THE 
LAW, THE THEORY, AND THE DATA (2013). 
Bupren01phine Medication-Assisted Treatment: J7ze Role ef Informed Consent 
53 
non-physician providers in OUD treatment, it is critical that these providers are aware 
of and prepared to support a patient's decision to receive medication-assisted treatment. 
To be able to inform patients in an honest and ethical manner, these non-physician 
providers need to be informed of treatments and prepared to confront their own biases 
so that they do not undermine medication treatment. Across the nation there are various 
state laws that discuss informed consent standards for psychologists, social workers, and 
other providers, so informed consent is not limited to physicians. 231 
CONCLUSION 
The unfortunate reality of the current status of B-MAT treatment is that scientific 
and medical research is seemingly ignored because of the existing bias against OUD 
patients.232 The benefits of informed consent could be portrayed through B-MAT 
treatment if the informed consent requirement is consistently enforced.233 While 
new challenges regarding B-MAT may arise in the future, or a new treatment option 
may become available, the use and enforcement of informed consent is crucial to the 
narrowing and elimination of the treatment gap. 
Because of the unique factors related to the OUD epidemic, specialized informed consent 
requirements should be implemented for the provider-ODD patient relationship. Before 
addressing regulations at the top level or deciding which treatment program is optimal, 
it is imperative that OUD patients are placed in the decision-making position and fully 
informed of all available treatments. As these patients learn about the comparative 
success of B-MAT, the disparity of the current treatment gap will become apparent. 
Legislators will be compelled to act and facilities will be forced to confront the research-
backed best practices and adapt to the demand for implementation of such practices. 
By trusting OUD patients to make decisions and to control their own treatments and 
futures, a strong provider-patient relationship will overcome the biases of the community 
and penetrate all models of OUD treatment. The past moral choices of a patient should 
have no bearing on the duties of a provider treating that patient. Whenever a provider-
OUD patient relationship is formed, the OUD patient should be informed of the available 
treatment options%not guilted into choosing an outdated, unsuccessful program that 
offers little chance of success.234 
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While this Article specifically examines the important role of informed consent in the 
doctor-OUD patient relationship, the principles of patient autonomy apply broadly to 
patient care. Healthcare is a dynamic field. 235 Diseases and their prevalence change 
with time as available information and treatments evolve.236 A strong provider-patient 
relationship is an important foundation in any patient care. 
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